Abi-Saab Walid 4
4 · uniQure N.V. · Filed May 12, 2026
Research Summary
AI-generated summary of this filing
uniQure (QURE) CMO Abi‑Saab Walid Exercises Options, Sells Shares
What Happened
Abi‑Saab Walid, Chief Medical Officer of uniQure (QURE), exercised/converted derivative awards and sold shares on May 8, 2026. The filing reports: exercised 25,000 shares at $5.59 (cash cost $139,750) and a conversion/exercise of 25,000 shares shown at $0.00 (derivative). On the same day he sold 25,000 shares at a weighted average price of $25.10 (proceeds ~$627,500) and 20,000 shares at $25.00 (proceeds $500,000), for total sale proceeds of approximately $1,127,500. These transactions were effected under a Rule 10b5‑1 plan.
Key Details
- Transaction date: May 8, 2026. Form 4 filed May 12, 2026 (timely within the two‑business‑day SEC window).
- Exercises/conversions: 25,000 shares acquired at $5.59 (cost $139,750); 25,000 shares listed as exercised/converted at $0.00 (derivative).
- Sales: 45,000 shares sold (25,000 at $25.10 weighted avg; 20,000 at $25.00). Price range for sales: $25.00–$25.29 (filing footnote). Total reported sale proceeds ≈ $1,127,500.
- Shares owned after transaction: not disclosed in the provided filing.
- Notable footnotes: transactions were made pursuant to a 10b5‑1 trading plan adopted Sept 26, 2025 (Footnote F1); sale price shown as a weighted average with range provided and further breakdown available on request (F2); the option referenced was granted Mar 1, 2024 with standard vesting schedule (F3).
Context: The pattern here is an exercise/ conversion of derivatives followed by same‑day open‑market sales — effectively realizing gains rather than an outright purchase (not a bullish purchase signal). The 10b5‑1 plan means the sales were pre‑arranged; filings are factual and do not indicate the insider’s motive.
Insider Transaction Report
- Exercise/Conversion
Ordinary Shares
[F1]2026-05-08$5.59/sh+25,000$139,750→ 214,669 total - Sale
Ordinary Shares
[F1][F2]2026-05-08$25.10/sh−25,000$627,500→ 189,669 total - Sale
Ordinary Shares
[F1]2026-05-08$25.00/sh−20,000$500,000→ 169,669 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-05-08−25,000→ 60,500 totalExercise: $5.59Exp: 2034-03-01→ Ordinary Shares (25,000 underlying)
Footnotes (3)
- [F1]The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.